Akari Therapeutics, Plc

NasdaqCM AKTX

Akari Therapeutics, Plc Net Income for the year ending December 31, 2023: USD -10.01 M

Akari Therapeutics, Plc Net Income is USD -10.01 M for the year ending December 31, 2023, a -43.54% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Akari Therapeutics, Plc Net Income for the year ending December 31, 2022 was USD -6.97 M, a 60.40% change year over year.
Akari Therapeutics, Plc Net Income for the year ending December 31, 2021 was USD -17.61 M, a -0.06% change year over year.
Akari Therapeutics, Plc Net Income for the year ending December 31, 2020 was USD -17.60 M, a 19.15% change year over year.
Akari Therapeutics, Plc Net Income for the year ending December 31, 2019 was USD -21.76 M, a -9.09% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqCM: AKTX

Akari Therapeutics, Plc

CEO	Dr. Samir Rashmikant Patel M.D.
IPO Date	Jan. 6, 2014
Location	United Kingdom
Headquarters	75/76 Wimpole Street
Employees	6
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Key trends

Past 5 years